タゾバクタム／ピペラシリン（TAZ／PIPC）投与時における用量調節の有効性と，腎及び肝機能障害の発現頻度

摘要

Tazobactam/piperacillin (TAZ/PIPC) is widely used in the treatment of infectious disease. In this study, three hundred and sixty-three patients who were treated with the recommended dose of TAZ/PIPC were investigated for the proportion of time above the minimum inhibitory concentration (TAM) and the frequency of renal and liver dysfunction. Of the whole patient population, 5.23, exhibited increased creatinine levels, 9.37 and 8.82 exhibited increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, respectively. The patients who exhibited high serum creatinine (SCr) levels before administration, exhibited significant increases of AST ( p =0.0121). The patients who exhibited low albumin levels before administration, exhibited significant decreases in renal function ( p =0.0041). In the case of a breakpoint (BP) of 64 μg/mL, the arrival probabilities of TAM of 30 and 50 were 99.4 and 76.9, respectively. We suggested that the dose of TAZ/PIPC should be adjusted according to the interview form finding and a TAM>50 (maximal bactericidal action).